TY - CHAP M1 - Book, Section TI - Practice Guidelines for Postanesthetic Care A1 - Bailin, Michael A1 - Spanakis, Spiro PY - 2000 T2 - Guidelines AB - |PrintPractice Guidelines for Postanesthetic CareComments by Michael T. Bailin, MDGuideline purpose: to improve outcome of care for post-operative / post-sedation patientsActionsLiterature EvidenceRecommendationsPostoperative Assessment & Monitoring of:Respiratory function1) Consultants and ASA members agree on recommendations2) New literature insufficient to further evaluatePerform periodic assessment of airway patency, respiratory rate, and SpO2Cardiovascular functionInsufficient on whether CV assessment decreases perioperative complicationsMonitoring of pulse and BP should be performed. ECG monitors should be immediately available.Neuromuscular function1) Suggests that neuromuscular blockade monitors are effective2) New literature insufficient to further evaluateNeuromuscular function testing valuable during emergence and recovery for patients who have received nondepolarizing neuromuscular blockersMental statusInsufficient regarding whether MS assessment decreases complications Mental status should be periodically assessedTemperatureInsufficient regarding routine assessment leading to fewer complicationsPatient temperature should be periodically assessedPainInsufficient regarding routine assessment of pain decreases complicationsPain should be periodically assessedNausea and vomitingInsufficient whether routine assessment leads to fewer complicationsRoutine assessment of nausea and vomiting should be performedFluid statusInsufficient regarding benefits of fluid status assessmentAssess postoperative hydration status in the PACU and manage as necessaryUrine output and voidingInsufficient regarding measurement of urine output and association with postop complicationsAssess urine output and voiding on a case-by-case basisDrainage and bleedingInsufficient on impact of measurementAssess drainage and bleeding when indicatedActionsLiterature EvidenceRecommendationsEmergence & Recovery:Prophylaxis & Treatment N/VSupports pre- and intraoperative use of antiemetics and insufficient on efficacy of multiple agents to treat N/VUse antiemetic agents to prevent and treat nausea and vomiting when indicated. Supplemental oxygenSupports use of oxygen to reduce incidence of hypoxemiaSupplemental oxygen can prevent and treat hypoxemia. Consultant experts remain equivocal on the routine use of oxygen during transport and in PACU.Normalizing patient temperatureInsufficient in showing fewer adverse outcomesNormothermia is desirable during emergence and recovery. Treating hypothermia with forced air warming systems is appropriatePharmacologic agents for reduction of shiveringMeperidine is more effective than other opioid agonists or agonist-antagonistsMeperidine should be used to treat patient shivering during emergence and recovery when clinically indicated. Hypothermia, should be treated by rewarming. Antagonism of benzodiazepinesSupports efficacy of flumazenilSpecific antagonists should be availableAntagonism of opioidsSupports efficacy of naloxone in reducing time to emergence and spontaneous ventilationSpecific antagonists should be availableAntagonism of NM Blockade Supports efficacy of anticholinesterase agentsSpecific antagonists should be administered for reversal of residual neuromuscular blockadeActionsLiterature EvidenceRecommendationsProtocol for Discharge:Voiding before dischargeInsufficient to evaluate benefitsRequiring urination before discharge only necessary for selected patientsDrinking clear fluids without vomitingOriginal literature equivocal, new literature insufficient to evaluate benefitsDrinking clear fluids not generally necessary; determine case-by-caseResponsible individual to accompany patient home Insufficient to evaluate benefitsAll patients should have a responsible escortMinimum mandatory stay in recoveryInsufficient to evaluate benefitsObserve until patient no longer at increased risk; mandatory minimum time not requiredSource: Anesthesiology 2013; 118(2):291-307. [go to full text of guideline] SN - PB - The McGraw-Hill Companies, Inc. CY - New York, NY Y2 - 2024/04/19 UR - accessanesthesiology.mhmedical.com/content.aspx?aid=5010063 ER -